Research ExplorerPublicationsDisturbed lipid and amino acid metabolisms in COVID-19 patie...

Disturbed lipid and amino acid metabolisms in COVID-19 patients

Standard

Disturbed lipid and amino acid metabolisms in COVID-19 patients. / Masoodi, Mojgan; Peschka, Manuela; Schmiedel, Stefan; Haddad, Munif; Frye, Maike; Maas, Coen; Lohse, Ansgar; Huber, Samuel; Kirchhof, Paulus; Nofer, Jerzy-Roch; Renné, Thomas.

In: J MOL MED, Vol. 100, No. 4, 04.2022, p. 555-568.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Masoodi, M, Peschka, M, Schmiedel, S, Haddad, M, Frye, M, Maas, C, Lohse, A, Huber, S, Kirchhof, P, Nofer, J-R & Renné, T 2022, 'Disturbed lipid and amino acid metabolisms in COVID-19 patients', J MOL MED, vol. 100, no. 4, pp. 555-568. https://doi.org/10.1007/s00109-022-02177-4

APA

Masoodi, M., Peschka, M., Schmiedel, S., Haddad, M., Frye, M., Maas, C., Lohse, A., Huber, S., Kirchhof, P., Nofer, J-R., & Renné, T. (2022). Disturbed lipid and amino acid metabolisms in COVID-19 patients. J MOL MED, 100(4), 555-568. https://doi.org/10.1007/s00109-022-02177-4

Vancouver

Masoodi M, Peschka M, Schmiedel S, Haddad M, Frye M, Maas C et al. Disturbed lipid and amino acid metabolisms in COVID-19 patients. J MOL MED. 2022 Apr;100(4):555-568. https://doi.org/10.1007/s00109-022-02177-4

Bibtex

@article{afc89deb8c41413fa6092ec3c6e06b93,
title = "Disturbed lipid and amino acid metabolisms in COVID-19 patients",
abstract = "The Coronavirus disease 2019 (COVID-19) pandemic is overwhelming the healthcare systems. Identification of systemic reactions underlying COVID-19 will lead to new biomarkers and therapeutic targets for monitoring and early intervention in this viral infection. We performed targeted metabolomics covering up to 630 metabolites within several key metabolic pathways in plasma samples of 20 hospitalized COVID-19 patients and 37 matched controls. Plasma metabolic signatures specifically differentiated severe COVID-19 from control patients. The identified metabolic signatures indicated distinct alterations in both lipid and amino acid metabolisms in COVID-19 compared to control patient plasma. Systems biology-based analyses identified sphingolipid, tryptophan, tyrosine, glutamine, arginine, and arachidonic acid metabolism as mostly impacted pathways in COVID-19 patients. Notably, gamma-aminobutyric acid (GABA) was significantly reduced in COVID-19 patients and GABA plasma levels allowed for stratification of COVID-19 patients with high sensitivity and specificity. The data reveal large metabolic disturbances in COVID-19 patients and suggest use of GABA as potential biomarker and therapeutic target for the infection.",
author = "Mojgan Masoodi and Manuela Peschka and Stefan Schmiedel and Munif Haddad and Maike Frye and Coen Maas and Ansgar Lohse and Samuel Huber and Paulus Kirchhof and Jerzy-Roch Nofer and Thomas Renn{\'e}",
note = "{\textcopyright} 2022. The Author(s).",
year = "2022",
month = apr,
doi = "10.1007/s00109-022-02177-4",
language = "English",
volume = "100",
pages = "555--568",
journal = "J MOL MED",
issn = "0946-2716",
publisher = "Springer",
number = "4",

}

RIS

TY - JOUR

T1 - Disturbed lipid and amino acid metabolisms in COVID-19 patients

AU - Masoodi, Mojgan

AU - Peschka, Manuela

AU - Schmiedel, Stefan

AU - Haddad, Munif

AU - Frye, Maike

AU - Maas, Coen

AU - Lohse, Ansgar

AU - Huber, Samuel

AU - Kirchhof, Paulus

AU - Nofer, Jerzy-Roch

AU - Renné, Thomas

N1 - © 2022. The Author(s).

PY - 2022/4

Y1 - 2022/4

N2 - The Coronavirus disease 2019 (COVID-19) pandemic is overwhelming the healthcare systems. Identification of systemic reactions underlying COVID-19 will lead to new biomarkers and therapeutic targets for monitoring and early intervention in this viral infection. We performed targeted metabolomics covering up to 630 metabolites within several key metabolic pathways in plasma samples of 20 hospitalized COVID-19 patients and 37 matched controls. Plasma metabolic signatures specifically differentiated severe COVID-19 from control patients. The identified metabolic signatures indicated distinct alterations in both lipid and amino acid metabolisms in COVID-19 compared to control patient plasma. Systems biology-based analyses identified sphingolipid, tryptophan, tyrosine, glutamine, arginine, and arachidonic acid metabolism as mostly impacted pathways in COVID-19 patients. Notably, gamma-aminobutyric acid (GABA) was significantly reduced in COVID-19 patients and GABA plasma levels allowed for stratification of COVID-19 patients with high sensitivity and specificity. The data reveal large metabolic disturbances in COVID-19 patients and suggest use of GABA as potential biomarker and therapeutic target for the infection.

AB - The Coronavirus disease 2019 (COVID-19) pandemic is overwhelming the healthcare systems. Identification of systemic reactions underlying COVID-19 will lead to new biomarkers and therapeutic targets for monitoring and early intervention in this viral infection. We performed targeted metabolomics covering up to 630 metabolites within several key metabolic pathways in plasma samples of 20 hospitalized COVID-19 patients and 37 matched controls. Plasma metabolic signatures specifically differentiated severe COVID-19 from control patients. The identified metabolic signatures indicated distinct alterations in both lipid and amino acid metabolisms in COVID-19 compared to control patient plasma. Systems biology-based analyses identified sphingolipid, tryptophan, tyrosine, glutamine, arginine, and arachidonic acid metabolism as mostly impacted pathways in COVID-19 patients. Notably, gamma-aminobutyric acid (GABA) was significantly reduced in COVID-19 patients and GABA plasma levels allowed for stratification of COVID-19 patients with high sensitivity and specificity. The data reveal large metabolic disturbances in COVID-19 patients and suggest use of GABA as potential biomarker and therapeutic target for the infection.

U2 - 10.1007/s00109-022-02177-4

DO - 10.1007/s00109-022-02177-4

M3 - SCORING: Journal article

C2 - 35064792

VL - 100

SP - 555

EP - 568

JO - J MOL MED

JF - J MOL MED

SN - 0946-2716

IS - 4

ER -